Ratings for Xencor XNCR were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 3 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Xencor and provided 12-month price targets. The average target is $37.5, accompanied by a high estimate of $50.00 and a low estimate of $32.00. Highlighting a 15.41% decrease, the current average has fallen from the previous average price target of $44.33.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Xencor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gregory Renza | RBC Capital | Maintains | Outperform | $32.00 | - |
| Etzer Darout | BMO Capital | Lowers | Outperform | $34.00 | $38.00 |
| David Nierengarten | Wedbush | Lowers | Outperform | $34.00 | $36.00 |
| Mara Goldstein | Mizuho | Lowers | Buy | $50.00 | $59.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xencor. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xencor compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Xencor's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Xencor's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Xencor analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Xencor: A Closer Look
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Xencor's Financial Performance
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Xencor's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 116.73%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Xencor's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -41.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Xencor's ROE excels beyond industry benchmarks, reaching -3.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Xencor's ROA stands out, surpassing industry averages. With an impressive ROA of -3.12%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Xencor's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
